Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Saol therapeutics","sponsor":"Kamada","pharmaFlowCategory":"D","amount":"$145.0 million","upfrontCash":"$95.0 million","newsHeadline":"Kamada Announces Strategic Transformational Transaction Positioning the Company as a Global Leader in the Plasma-Derived Hyperimmune Market Through the Acquisition of a Portfolio of Four FDA-Approved Commercial Products","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"November 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Saol therapeutics","sponsor":"Amneal Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Amneal Acquires Saol Therapeutics\u2019 Baclofen Franchise","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2022","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved"},{"orgOrder":0,"company":"Saol therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Saol Therapeutics Announces Enrollment Achievement in Pivotal Phase 3 Trial for Rare Mitochondrial Disease - Pyruvate Dehydrogenase Complex Deficiency (PDCD)","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III"},{"orgOrder":0,"company":"Saol therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Saol Therapeutics Announces Completion of Enrollment in Both the Phase II COMPASS Osteoarthritis Knee Pain Trial and the Phase II RAISE Limb Spasticity Trial","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by Saol therapeutics

    Menu

    Saol therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Saol therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Saol Therapeutics Announces Completion of Enrollment in Both the Phase II COMPASS Osteoarthritis Knee Pain Trial and the Phase II RAISE Limb Spasticity Trial

              Details:

              SL-1002 is a novel, chemoneurolytic injection, that utilizes Saol's proprietary CYCLOPHLEX™ technology, which is investigated for the treatment of Osteoarthritis Knee Pain.

              Lead Product(s): SL-1002

              Therapeutic Area: Musculoskeletal Product Name: SL-1002

              Highest Development Status: Phase II Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 19, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Saol therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Saol Therapeutics Announces Enrollment Achievement in Pivotal Phase 3 Trial for Rare Mitochondrial Disease - Pyruvate Dehydrogenase Complex Deficiency (PDCD)

              Details:

              Dichloroacetate (SL-1009) has the potential to be the 1st approved medication for the mitochondrial disease PDCD. DCA inhibits PDKs to stimulate residual PDC activity and increase energy (ATP) production by mitochondria.

              Lead Product(s): Dichloroacetic Acid

              Therapeutic Area: Rare Diseases and Disorders Product Name: SL-1009

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 04, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Saol therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Amneal Acquires Saol Therapeutics’ Baclofen Franchise

              Details:

              Amneal is adding Saol’s experienced institutional commercial team for Lioresal that can be utilized to support product launches, including biosimilar products, filgrastim (biosimilar for Neupogen), pegfilgrastim (biosimilar for Neulasta) & bevacizumab (biosimilar for Avastin).

              Lead Product(s): Baclofen

              Therapeutic Area: Musculoskeletal Product Name: Lioresal

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Amneal Pharmaceuticals

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Acquisition January 05, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Saol therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Kamada Announces Strategic Transformational Transaction Positioning the Company as a Global Leader in the Plasma-Derived Hyperimmune Market Through the Acquisition of a Por...

              Details:

              Under the terms of the agreement, Kamada Inc., will be responsible for the commercialization of the CYTOGAM®, WINRHO®, HEPAGAM B®, and VARIZIG® in the U.S., including direct sales to wholesalers and local distributers.

              Lead Product(s): Cytomegalovirus Immune Globulin [Human],Ganciclovir

              Therapeutic Area: Infections and Infectious Diseases Product Name: Cytogam

              Highest Development Status: Approved Product Type: Large molecule

              Partner/Sponsor/Collaborator: Kamada

              Deal Size: $145.0 million Upfront Cash: $95.0 million

              Deal Type: Acquisition November 22, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY